Skip to main content

LCD L34522: Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive Disorder

LCD L34522, Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive Disorder, is the Local Coverage Determination that First Coast Service Options, Inc. applies to claims from 1 state plus 2 territories (FL, PR, VI), effective 2022-12-11 and first in force 2015-10-01. The policy text runs 802 words, and its billing and coding article A57647 lists 2 ICD-10-CM codes that support medical necessity for 3 procedure codes. 5 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 2 covered ICD-10-CM codes: the same total as L33398 (Wellpoint Federal, 2 codes, revised 2026-08-09) and the same total as L34641 (Wisconsin Physicians Service Insurance Corporation, 2 codes, revised 2026-03-26).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
First Coast Service Options, Inc.
States and territories
3
FL PR VI
Revision effective
2022-12-11
Original effective
2015-10-01
Policy text
802 words
Covered ICD-10 codes (articles)
2

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L34522
ContractContractorTypeStates
09101First Coast Service Options, Inc.A and B MACFL
09201First Coast Service Options, Inc.A and B MACPR VI
09102First Coast Service Options, Inc.A and B MACFL
09202First Coast Service Options, Inc.A and B MACPR
09302First Coast Service Options, Inc.A and B MACVI

Billing and coding article A57647: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A57647 (Billing and Coding: Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive Disorder) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A57647: Billing and Coding: Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive Disorder (Billing and Coding, effective 2023-07-06)

Covered ICD-10-CM codes
2
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
3
Full article
cms.gov record
First 2 covered ICD-10-CM codes in A57647
ICD-10-CMDescription (FY2027)
F32.2Major depressive disorder, single episode, severe without psychotic features
F33.2Major depressive disorder, recurrent severe without psychotic features

Procedure codes: 90867, 90868, 90869.

Coverage indications, limitations and medical necessity

Compliance with the provisions in this LCD may be monitored and addressed through post payment data analysis and subsequent medical review audits.

History/Background and/or General Information

Transcranial Magnetic Stimulation (TMS) is FDA approved for the treatment of depression and obsessive-compulsive disorders. 1-3 It is a non-invasive procedure that uses pulsed magnetic fields to induce an electric current in a localized region of the cerebral cortex. 4-7 An electromagnetic coil is placed on the scalp inducing a focal current into the brain that temporarily modulates cerebral cortical function. A capacitor discharge provides electrical current in an alternating on/off pulse. Based on stimulation parameters this may be adjusted to alter the excitability of the targeted structures in specific cortical regions. 8 The electromagnetic current parameters include cranial location, frequency, strength, width, and volume dependent on the motor threshold that is individualized for each patient. 1,2

TMS is delivered daily in an outpatient setting without anesthesia or analgesia for up to six weeks and there are no restrictions related to activities before or after treatment (e.g., driving, working, operating heavy machinery). 9

Definitions

Major Depressive Disorder: The diagnosis based on the definition in the current Diagnostic and Statistical Manual of Mental Disorders (DSM). It is based on symptoms, characteristics, and requirements that are needed in order to be diagnosed with depression.

Major Depressive Disorder – Severe: A subcategory of major depressive disorder as differentiated within the DSM manual from mild, moderate, and severe. For example: “The number of symptoms is substantially in excess of that required to make the diagnosis, the intensity of the symptoms is seriously distressing and unmanageable, and the symptoms markedly interfere with social and occupational functioning.” 10

Failure of a trial of a pharmacological agent: The failure of one or more psychopharmacological medications that are administered at both an adequate dose and adequate duration that are consistent with the FDA label and with a duration that would elicit a favorable response. 9,11-13

Intolerance of a psychopharmacologic agent: Intolerable side effect(s) that are not expected to diminish or resolve with continued administration of the medication. 5,14,15

Motor Threshold (MT) Intensity: The minimum stimulator setting that induces an observable motor response when applied to the patient. 1

Frequency: The number of pulses delivered per second, measured in Hertz (Hz). 1

Magnetic Field Strength: The measurement of voltage induced to the identified area. 1

Pulse Width: The duration of time from the peak of a pulse to the peak of the next pulse. 1

Stimulation Volume: The region of cortical tissue that is stimulated based on the Motor Threshold identified for the individual patient. 1

Covered Indications

TMS of the brain for severe MDD, single or recurrent episode, is considered medically reasonable and necessary for up to six weeks 3,5,6,16-19 when the following criteria are met:

• The patient has a confirmed diagnosis of severe MDD as defined by the current DSM.

AND

• The patient has demonstrated a failure of one or more trials of a pharmacological medication and/or demonstrates an intolerance to psychopharmacologic medications as defined in the definition section above.

AND

• The order for TMS procedure is written by a psychiatrist (MD or DO), who has examined the patient face to face and reviewed the record. 20

Limitations

The following is considered an ABSOLUTE CONTRAINDICATION:

The presence of a medically implanted magnetic-sensitive device or other implanted metal items including, but not limited to, a cochlear implant, implanted cardiac defibrillator (ICD), pacemaker, vagus nerve stimulator (VNS), metal aneurysm clips/coils, staples, or stents, that are located less than or equal to 30 cm from the TMS magnetic coil. 1,6,15

The following are considered RELATIVE CONTRAINDICATIONS:

• The presence of a seizure disorder or any history of seizures (except those induced by Electroconvulsive therapy [ECT] or isolated febrile seizures in infancy without subsequent treatment or recurrence).

• The presence of acute or chronic psychotic symptoms or disorders in the current depressive episode.

• The presence of any neurological conditions including epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, history of repetitive or severe head trauma, or primary or secondary tumors in the central nervous system.

The following is considered not medically reasonable and necessary:

All other uses of TMS, including the use of TMS for OCD. 7,12,20-23

Provider Qualifications

Services will be considered medically reasonable and necessary when all aspects of care are within the scope of practice of the provider’s professional licensure, when performed according to the supervision requirements per state scope of practice laws, and when all procedures are performed by appropriately trained providers in the appropriate setting.

Notice: Services performed for any given diagnosis must meet all the indications and limitations stated in this LCD, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.

Summary of evidence (opening)

This summary of evidence focuses on the use of TMS in the treatment of MDD and TMS in the treatment of OCD and the use of TMS following one or more failed trials of pharmacological agents to determine whether the evidence is sufficient to draw conclusions about improved health outcomes for the Medicare population. In general, improved health outcomes of interest include patient quality of life and function.

In addition to reviewing evidence presented at a Multi-jurisdictional CAC Meeting and literature submitted with reconsiderations, a literature search was conducted using the following key words and phrases: TMS and OCD; TMS treatment for OCD; RCT of OCD TMS; OCD for deep transcranial magnetic stimulation (dTMS); Non-invasive/non-pharmacological OCD/depression treatment; and TMS as OCD treatment; scoring of Hamilton Rating Scale for Depression (HAMD); Montgomery-Asberg Depression Scale (MARDS) treatment parameters; DSM mild, moderate, severe depression. Along with various association guidelines. The highest level of evidence consisting of large randomized controlled trials (RCTs), multi-site RCTs, peer reviews and society endorsements were followed.

Clinical Trials

Rush et al 16 reviewed the protocol implemented by the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) that include a RCT that began with 3,671 patients who would receive the first of four levels of treatment beginning with medication. At any time during the protocol, if a patient achieved remission, they could then opt to be followed in a long-term naturalistic review that would last 12 months. The study began with 41 clinical sites consisting of patients between 18-75 years of age, diagnosed with MDD, and not previously exposed to any treatment protocol in the first and second treatment steps.

The contractor cites 85 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2022-12-11
MCD version
29
Derived from
L33676

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the First Coast Service Options, Inc. hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L34522 cover?

Transcranial Magnetic Stimulation (TMS) is FDA approved for the treatment of depression and obsessive-compulsive disorders. 1-3 It is a non-invasive procedure that uses pulsed magnetic fields to induce an electric current in a localized region of the cerebral cortex. 4-7 An electromagnetic coil is placed on the scalp inducing a focal current into the brain that temporarily modulates cerebral cortical function. The full 802-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L34522 apply to?

First Coast Service Options, Inc. applies it to Medicare claims in 1 state plus 2 territories: FL, PR, VI. It binds only that contractor; 5 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L34522?

The companion billing and coding article A57647 lists 2 ICD-10-CM codes in 1 group that support medical necessity; the first 2 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L34522?

A denial under LCD L34522 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A57647's 2 covered diagnosis codes, then file a redetermination with First Coast Service Options, Inc. within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.